Dermata Gross Profit from 2010 to 2025

DRMAW Stock

USD 0.02 0.00 0.000005%

Dermata Therapeutics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit will likely drop to -388.81 in 2025. Gross Profit is the profit Dermata Therapeutics Warrant makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

(370.30)

Current Value

(388.81)

Quarterly Volatility

507.20911428

Credit Downgrade

Yuan Drop

Covid

Check Dermata Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dermata Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 237.1 K, Depreciation And Amortization of 9.7 M or Interest Expense of 111.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.0014. Dermata financial statements analysis is a perfect complement when working with Dermata Therapeutics Valuation or Volatility modules.

Check out the analysis of Dermata Therapeutics Correlation against competitors.

For more information on how to buy Dermata Stock please use our How to Invest in Dermata Therapeutics guide.

Latest Dermata Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Dermata Therapeutics Warrant over the last few years. Gross profit is a required income statement account that reflects total revenue of Dermata Therapeutics Warrant minus its cost of goods sold. It is profit before Dermata Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Dermata Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dermata Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Dermata Gross Profit Regression Statistics

	Arithmetic Mean	(974.82)
	Geometric Mean	806.90
	Coefficient Of Variation	(52.03)
	Mean Deviation	475.23
	Median	(1,355)
	Standard Deviation	507.21
	Sample Variance	257,261
	Range	1K
	R-Value	0.83
	Mean Square Error	84,349
	R-Squared	0.69
	Significance	0.000062
	Slope	88.75
	Total Sum of Squares	3.9M

Dermata Gross Profit History

	2025	-388.81
	2024	-370.3
	2020	-322.0

Other Fundumenentals of Dermata Therapeutics

Gross Profit Margin

Dermata Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Net Working Capital	Short Term Debt	Common Stock	Capital Stock	Net Receivables	Short Term Investments
Total Assets		1.0	-0.95	-0.12	-1.0	0.54	-0.95	1.0	-0.11	0.41	1.0	-0.01	0.41	-0.56	-0.79	-0.81	-0.95
Total Stockholder Equity	1.0		-0.95	-0.14	-1.0	0.56	-0.95	1.0	-0.09	0.42	1.0	0.01	0.42	-0.58	-0.79	-0.82	-0.95
Current Deferred Revenue	-0.95	-0.95		0.12	0.93	-0.44	1.0	-0.95	0.11	-0.31	-0.95	0.01	-0.31	0.53	0.75	0.74	1.0
Net Debt	-0.12	-0.14	0.12		0.12	-0.71	0.12	-0.12	-0.95	-0.58	-0.12	-0.99	-0.58	0.83	0.15	0.35	0.12
Retained Earnings	-1.0	-1.0	0.93	0.12		-0.55	0.93	-1.0	0.11	-0.42	-1.0	0.01	-0.42	0.56	0.79	0.81	0.93
Accounts Payable	0.54	0.56	-0.44	-0.71	-0.55		-0.44	0.54	0.52	0.59	0.54	0.63	0.59	-0.84	-0.66	-0.85	-0.44
Long Term Debt	-0.95	-0.95	1.0	0.12	0.93	-0.44		-0.95	0.11	-0.31	-0.95	0.01	-0.31	0.53	0.75	0.74	1.0
Total Liab	1.0	1.0	-0.95	-0.12	-1.0	0.54	-0.95		-0.11	0.41	1.0	-0.01	0.41	-0.56	-0.79	-0.81	-0.95
Net Invested Capital	-0.11	-0.09	0.11	-0.95	0.11	0.52	0.11	-0.11		0.61	-0.11	0.97	0.61	-0.72	0.06	-0.14	0.11
Short Long Term Debt	0.41	0.42	-0.31	-0.58	-0.42	0.59	-0.31	0.41	0.61		0.41	0.54	1.0	-0.83	-0.34	-0.58	-0.31
Total Current Assets	1.0	1.0	-0.95	-0.12	-1.0	0.54	-0.95	1.0	-0.11	0.41		-0.01	0.41	-0.56	-0.79	-0.81	-0.95
Net Working Capital	-0.01	0.01	0.01	-0.99	0.01	0.63	0.01	-0.01	0.97	0.54	-0.01		0.54	-0.76	-0.02	-0.22	0.01
Short Term Debt	0.41	0.42	-0.31	-0.58	-0.42	0.59	-0.31	0.41	0.61	1.0	0.41	0.54		-0.83	-0.34	-0.58	-0.31
Common Stock	-0.56	-0.58	0.53	0.83	0.56	-0.84	0.53	-0.56	-0.72	-0.83	-0.56	-0.76	-0.83		0.46	0.71	0.53
Capital Stock	-0.79	-0.79	0.75	0.15	0.79	-0.66	0.75	-0.79	0.06	-0.34	-0.79	-0.02	-0.34	0.46		0.91	0.75
Net Receivables	-0.81	-0.82	0.74	0.35	0.81	-0.85	0.74	-0.81	-0.14	-0.58	-0.81	-0.22	-0.58	0.71	0.91		0.74
Short Term Investments	-0.95	-0.95	1.0	0.12	0.93	-0.44	1.0	-0.95	0.11	-0.31	-0.95	0.01	-0.31	0.53	0.75	0.74

Click cells to compare fundamentals

About Dermata Therapeutics Financial Statements

Dermata Therapeutics investors use historical fundamental indicators, such as Dermata Therapeutics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Dermata Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Gross Profit	(370.30)	(388.81)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
S	SentinelOne
GM	General Motors

Additional Tools for Dermata Stock Analysis

When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC